Delivery Technology Solutions, Inc. (Pinksheets:DTSL), the leader in delivery management technology, has completed participation at one of the largest restaurant franchisee conventions, held July 22-25, 2010. Its UDS division attended the convention by invitation of the leading franchisor, and was able to showcase its large corporate catering and event management delivery technology platform to many of the thousands of convention attendees, and a range of other potential partners in the industry and associated industries.
“This was our first opportunity to interact face-to-face on a large scale with franchisees from all across American, Canadian, European, Middle Eastern and Asian markets,” said Ryan Coblin, CEO. “We could shake their hands, explain the opportunities our solutions offer, answer their questions and sign them up for follow-up contacts.”
Over the three-day event the company was successful in signing up franchisees that own thousands of locations, and multiple-territory development agents who represent thousands more. These signed prospects will be contacted by the franchisor and UDS to offer them optional programs to expand their customer base, increase sales and build new profits for their restaurants. Qualified franchisees are enrolled in the optional programs, and then UDS proprietary software is implemented at their unit, so orders may be received from the UDS Call Center and Online Ordering technology.
“As exciting as it was to meet the franchisees and development agents,” Mr. Coblin commented, “We also connected with old and new friends in the vendor community, representing some of the most famous brands in the industry, and other Fortune 500 companies, to open and further discussions toward cooperative partnerships to develop greater opportunities within the franchise population.”
Genesco Inc. (NYSE: GCO) has declared dividends on the various classes of its preferred stock for the quarter ending October 30, 2010, payable on October 30, 2010, to shareholders of record on October 15, 2010.
Genesco Inc., a Nashville-based specialty retailer, sells footwear, headwear and accessories in more than 2,260 retail stores in the United States and Canada, principally under the names Journeys, Journeys Kidz, Shi by Journeys, Johnston & Murphy, Underground Station, Hatworld, Lids, Hat Shack, Hat Zone, Head Quarters and Cap Connection, and on internet websites www.journeys.com, www.journeyskidz.com, www.shibyjourneys.com, www.undergroundstation.com, www.johnstonmurphy.com , www.dockersshoes.com, and www.lids.com. The Company also sells footwear at wholesale under its Johnston & Murphy brand and under the licensed Dockers brand.
Genesee & Wyoming Inc. (NYSE: GWR) reports that Michael O. Miller has joined the company as Chief Commercial Officer, North America. The newly created position is based in GWI�s office in Jacksonville, Fla., and reports to the Chief Executive Officer.
Mr. Miller has more than 15 years of logistics and transportation industry experience, most recently as General Manager of Norfolk Southern�s Modalgistics Supply Chain Solutions. Prior to Norfolk Southern, he was Vice President Strategic Development of Derivion Corp. and held logistics-related positions with Georgia-Pacific and Roadway Express. Mr. Miller holds a B.S. in industrial engineering and an M.S. in business management from North Carolina State University.
Genesee & Wyoming owns and operates short line and regional freight railroads in the United States, Canada, Australia and the Netherlands. Operations currently include 62 railroads organized in nine regions, with approximately 6,000 miles of owned and leased track and approximately 3,400 additional miles under track access arrangements. Genesee & Wyoming provides rail service at 16 ports in North America and Europe and performs contract coal loading and railcar switching for industrial customers.
GenMark Diagnostics, Inc. (NASDAQ:GNMK), a provider of automated, multiplex molecular diagnostic testing systems, reports that their eSensor Warfarin Sensitivity Test has been selected for use in a new pivotal Warfarin clinical study; the WARFARIN Trial (Warfarin Adverse event Reduction For Adults Receiving genetic testing at therapy INitiation). The trial will seek to evaluate the value of genetic testing on reducing adverse events associated with Warfarin therapy.
Eligible patients in this clinical study will be reimbursed by the Centers for Medicare and Medicaid Services (CMS) through a temporary code developed to enable the implementation of pharmacogenomic testing under the Coverage with Evidence Development (CED) provision in the Social Security Act. GenMark�s selection for use in the WARFARIN trial was made by Iverson Genetics. �We selected GenMark Diagnostics� technology for its ability to provide accurate and reliable results. The XT-8 allows fast processing and simple interpretation of patient results,� stated Dean Sproles, CEO of Iverson Genetics.
GenMark, a provider of automated, multiplex molecular diagnostic testing systems, detects and measures DNA and RNA targets to diagnose disease and to optimize the treatment of patients and is focused on developing and commercializing its eSensor detection technology. GenMark�s XT-8 System is designed to support a broad range of molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. GenMark has developed four diagnostic tests for use with the XT-8 System, including its Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test and Thrombophilia Risk Test which have received clearance from the Food and Drug Administration.
No comments:
Post a Comment